Kapspargo (metoprolol succinate)
Indications for Prior Authorization
Kapspargo (metoprolol succinate) capsules extended-release
-
For diagnosis of Hypertension
Indicated for the treatment of hypertension, to lower blood pressure. -
For diagnosis of Angina Pectoris
Indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance. -
For diagnosis of Heart Failure
Indicated to reduce the risk of cardiovascular mortality and heart-failure hospitalization in patients with heart failure.
Criteria
Kapspargo
Step Therapy
Length of Approval: 12 Month(s)
- Requested drug is being used for a Food and Drug Administration (FDA)-approved indication AND
- Trial and failure (of a minimum 30 day supply), contraindication, or intolerance to two of the following generics:
- metoprolol tartrate
- metoprolol succinate ER
- bisoprolol
- betaxolol
- carvedilol IR
- carvedilol ER
- labetalol
- atenolol
- acebutolol
- propranolol IR
- propranolol ER
- pindolol
- nadolol
P & T Revisions
2024-05-17, 2023-05-12, 2022-07-21, 2022-06-01, 2021-03-23
References
- Kapspargo Prescribing Information. Sun Pharmaceutical Industries, Inc. Cranbury, NJ. April 2023.
Revision History
- 2024-05-17: 2024 Annual Review
- 2023-05-12: 2023 UM Annual Review. No criteria changes. Added in "of a minimum 30 day supply" to trial duration requirement and updated references
- 2022-07-21: Clarified authorization duration.
- 2022-06-01: Annual Review. Added FDA approved diagnosis requirement to criteria.
- 2021-03-23: 2021 UM Annual Review.
HEALTHY LIVING